LEO Pharma

Further shuffling at Leo Pharma as dermatology drugmaker splits R&D
Further shuffling at Leo Pharma as dermatology drugmaker splits R&D
Endpoints
LEO Pharma
R&D
dermatology
Flag link:
Leo Pharma announces positive results for hand eczema study
Leo Pharma announces positive results for hand eczema study
Pharmaphorum
LEO Pharma
clinical trials
eczema
chronic hand eczema
delgocitinib
Flag link:
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme
Fierce Biotech
LEO Pharma
Pharma CEOs
Christophe Bourdon
Flag link:
Leo Pharma’s Tralokinumab News: What You Need to Know
Leo Pharma’s Tralokinumab News: What You Need to Know
BioSpace
LEO Pharma
Adtralza
FDA
atopic dermatitis
Flag link:
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
Endpoints
LEO Pharma
FDA
atopic dermatitis
eczema
monoclonal antibodies
Dupixent
Flag link:
LEO Pharma’s new R&D lead on driving agility in drug development
LEO Pharma’s new R&D lead on driving agility in drug development
Pharmaforum
LEO Pharma
R&D
Jörg Möller
Flag link:
Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA
Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA
Endpoints
LEO Pharma
psoriasis
Sanofi
Dupixent
LP0058
Flag link:
LEO eyeing 2021 US launch for eczema drug tralokinumab
LEO eyeing 2021 US launch for eczema drug tralokinumab
Pharmaforum
LEO Pharma
eczema
tralokinumab
Sanofi
Dupixent
Flag link:
AI drug discovery startup strikes partnership with LEO Pharma
AI drug discovery startup strikes partnership with LEO Pharma
MedCity News
Repurpose.AI
LEO Pharma
drug discovery
dermatology
Flag link:
AAD 2020 – Leo’s eczema wildcard proves tame
AAD 2020 – Leo’s eczema wildcard proves tame
EP Vantage
LEO Pharma
Sanofi
Regeneron
eczema
atopic dermatitis
AAD
tralokinumab
Flag link:
LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
Endpoints
LEO Pharma
eczema
asthma
clinical trials
FB825
China
Flag link:
Leo's Dupixent rival hits all endpoints in pivotal program
Leo's Dupixent rival hits all endpoints in pivotal program
Fierce Biotech
LEO Pharma
atopic dermatitis
tralokinumab
Sanofi
Regeneron
Dupixent
Flag link:
LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million
LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million
CP Wire
LEO Pharma
PellePharm
Gorlin Syndrome
dermatology
Flag link:
LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million
LEO Pharma
PellePharm
Gorlin Syndrome
Flag link:
LEO Pharma Closes Acquisition of Bayer’s Prescription Dermatology Business in the US
Bayer
LEO Pharma
Flag link:
Bayer sells prescription dermatology brands to Denmark's Leo Pharma
Bayer sells prescription dermatology brands to Denmark's Leo Pharma
Reuters
Bayer
LEO Pharma
dermatology
M&A
Flag link:
UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market
UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market
CP Wire
UTILITY Therapeutics
antibiotics
LEO Pharma
Flag link:
EMA recommends 11 drugs for approval in May meeting
EMA recommends 11 drugs for approval in May meeting
BioPharma Dive
EMA
Europe
Sanofi
AstraZeneca
LEO Pharma
Novartis
Pfizer
Flag link:
AstraZeneca sells off dermatology drug rights to LEO Pharma
AstraZeneca sells off dermatology drug rights to LEO Pharma
BioPharma Dive
AstraZeneca
dermatology
LEO Pharma
M&A
Flag link:
Top 20 biotech licensing deals in H1 2012
Top 20 biotech licensing deals in H1 2012
Fierce Biotech
Xenon
Virobay
Tolero Pharmaceuticals
Threshold Pharmaceuticals
Novartis
Merck KGaA
Merck
MannKind
licensing
Janssen
Isis Pharmaceuticals
Ironwood
Inhibrx Thrombogenics
GSK
Genmab
Genentech
Galapagos
Forma Therapeutics
Endocyte
Endo
Enanta
Celgene
Bristol-Myers Squibb
Boehringer Ingelheim
Bionomics
Biogen Idec
BioDelivery Sciences
AstraZeneca
Angiochem
AC Immune
Abbott Laboratories
LEO Pharma
Flag link:

Pages